Micafungin for the treatment of invasive aspergillosis

Enoch, David; Idris, Saad F; Aliyu, Sani H.; Micallef, Christianne; Sule, Olajumoke; Karas, J. A.

doi:10.1016/j.jinf.2014.01.007

Cited by 30 publications

(23 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Micafungin has demonstrated in vitro and in vivo activity against Aspergillus spp. (33,35); however, the obvious development of the obstructive material was observed in the airway under bronchoscopy during micafungin treatment in the present patient; which suggests that that Aspergillus may develop during micafungin therapy (36). Renal dysfunction is frequently observed in patients receiving liposomal AmB (37), which might have limited the use of this agent in the present patient.…”

Section: Discussioncontrasting

confidence: 60%

Fulminant Laryngeal-tracheobronchial-pulmonary Aspergillosis: A Rare and Fatal Complication in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Tao¹,

Zhang²,

Xue

et al. 2017

Intern. Med.

View full text Add to dashboard Cite

A 23-year-old man who had previously undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia was diagnosed with invasive laryngeal-tracheobronchial-pulmonary aspergillosis after presenting with a persistent dry cough at six months post-transplantation based on the findings of laryngoscopy and fiberoptic bronchoscopy. A fiberoptic bronchoscope was used to remove the obstructive material from the patient's airway and posaconazole plus caspofungin were administered to successfully to treat the patient. Our report suggests that laryngoscopy and fiberoptic bronchoscopy should be considered as alternative approaches to the diagnosis and treatment of allo-HSCT recipients with persistent respiratory symptoms when invasive laryngeal aspergillosis and invasive tracheobronchial aspergillosis are suspected.

show abstract

Section: Discussioncontrasting

confidence: 60%

Fulminant Laryngeal-tracheobronchial-pulmonary Aspergillosis: A Rare and Fatal Complication in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Tao¹,

Zhang²,

Xue

et al. 2017

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…The findings from the current analyses showed that micafungin is well tolerated, with a low incidence of ADRs, serious ADRs, and AEs leading to discontinuation of treatment. Overall, the data add to the growing body of evidence demonstrating the effectiveness and tolerability of micafungin for the treatment of patients with invasive fungal infections; however, it is difficult to compare this trial directly with others because of differences in the patient populations and in the way that treatment success was evaluated [ 1 , 8 – 10 , 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Zheng

Xiao-bo²,

Luo

et al. 2018

Adv Ther

View full text Add to dashboard Cite

IntroductionInvasive fungal infections (IFIs) are a significant health problem in immunocompromised patients, resulting in substantial morbidity, mortality, and healthcare costs. Micafungin is a broad-spectrum echinocandin with activity against Candida and Aspergillus spp. This was a multicenter, non-comparative, retrospective observational study that evaluated the effectiveness and tolerability of intravenously administered micafungin for treating IFIs caused by Candida and Aspergillus spp.MethodsAdult patients in China who had received at least one dose of intravenously administered micafungin were eligible. Retrospective data (May 2008–April 2015) were extracted from patients’ medical files and recorded using electronic data capture. The primary endpoint was overall success rate (patients with complete or partial response). Subgroup analyses determined effectiveness according to diagnostic certainty, fungal species, type of IFI, duration of micafungin treatment, and daily dose of micafungin. Tolerability, including the incidence of adverse events (AEs), was also assessed.ResultsOverall, 2555 patients who received at least one dose of micafungin were identified. The mean duration of treatment and mean daily dose were 10.2 days and 133.0 mg, respectively. The overall success rate was 60.8%; this was significantly higher in patients who received treatment for at least 1 week (range 67.9–71.6% [mean 69.2%]) compared with less than 1 week (47.8%; P < 0.0001), and those who received 50–100 mg (65.7%) compared with other daily doses (range 42.9–60.1% [mean 59.0%]; P = 0.0011). Success rates in Candida- and Aspergillus-infected patients were similar (61.9% and 56.8%, respectively). AEs and adverse drug reactions were observed in 36.2% and 4.5% of patients, respectively. The majority of AEs were mild, while discontinuation due to AEs was low (2.3%).ConclusionMicafungin is effective and well tolerated for the treatment of patients with IFIs in China, as demonstrated in Candida- and Aspergillus-infected adults. Subgroup analyses highlighted the potential benefits of treating IFIs with micafungin for a minimum of 1 week.Trial registrationClinicalTrials.gov identifier NCT02678598.FundingAstellas Pharma Inc.Electronic supplementary materialThe online version of this article (10.1007/s12325-018-0762-5) contains supplementary material, which is available to authorized users.

show abstract

“…Echinocandins have generally favorable safety and tolerability profiles with adequate pharmacokinetics and few drug interactions 1,2) . Moreover, in recent years, a large amount of clinical evidence for echinocandins have been accumulated [3][4][5][6][7][8] . In consequence, the Infectious Diseases Society of America (IDSA), the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the Japanese Society for Medical Mycology (JSMM), and the Japanese Mycoses Forum (JMF) recommend echinocandins as initial therapy for invasive candidiasis in their clinical guidelines [9][10][11][12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

Role of <I>FKS</I> Gene in the Susceptibility of Pathogenic Fungi to Echinocandins

Hori

Shibuya

2018

Medical Mycology Journal

View full text Add to dashboard Cite

Echinocandins are antifungal agents that specifically inhibit the biosynthesis of 1,3-β-D-glucan, a major structural component of fungal cell walls. Echinocandins are recommended as first-line or alternative/salvage therapy for candidiasis and aspergillosis in antifungal guidelines of various countries. Resistance to echinocandins has been reported in recent years. The mechanism of echinocandin resistance involves amino acid substitutions in hot spot regions of the FKS gene product, the catalytic subunit of 1,3-β-D-glucan synthase. This resistance mechanism contributes to not only acquired resistance in Candida spp., but also inherent resistance in some pathogenic fungi. An understanding of the echinocandin resistance mechanism is important to develop both effective diagnosis and treatment options for echinocandin-resistant fungal diseases.

show abstract

Micafungin for the treatment of invasive aspergillosis

Cited by 30 publications

References 110 publications

Fulminant Laryngeal-tracheobronchial-pulmonary Aspergillosis: A Rare and Fatal Complication in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Fulminant Laryngeal-tracheobronchial-pulmonary Aspergillosis: A Rare and Fatal Complication in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Role of <I>FKS</I> Gene in the Susceptibility of Pathogenic Fungi to Echinocandins

Contact Info

Product

Resources

About